Drug Profile
TK 39
Alternative Names: TK-39Latest Information Update: 12 Oct 2023
Price :
$50
*
At a glance
- Originator Tosk
- Class Cardiovascular therapies; Chemoprotectants; Nitrogen oxides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 12 Oct 2023 TK 39 is still in preclinical trials for Cardiovascular disorders in USA (Tosk pipeline, October 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 04 Jan 2018 Preclinical development is ongoing in USA